Emergence and spread of vancomycin resistance among enterococci in Europe by Werner, Guido et al.
  EUROSURVEILLANCE  Vol .  13 ·  Issue 47 ·  20 November  2008 ·  www.eurosurveillance.org 1
R ev i ew  ar ti cles
E m E r g E n c E  a n d  s p r E a d  o f  va n c o m yc i n  r E s i s ta n c E 
a m o n g  E n t E r o c o c c i  i n  E u r o p E
G Werner (wernerg@rki.de)1, T M Coque2, A M Hammerum3, R Hope4, W Hryniewicz5, A Johnson4, I Klare1, K G Kristinsson6, 
 R Leclercq7, C H Lester3, M Lillie4, C Novais8,9, B Olsson-Liljequist10, L V Peixe8, E Sadowy5, G S Simonsen11, J Top12,  
J Vuopio-Varkila13, R J Willems12, W Witte1, N Woodford4
1. Robert Koch-Institute, Wernigerode Branch, Wernigerode, Germany
2. University Hospital Ramón y Cajal, Madrid, Spain
3. Statens Serum Institute, Copenhagen, Denmark
4. Health Protection Agency Centre for Infections, London, United Kingdom
5. National Medicines Institute, Warsaw, Poland
6. Department of Clinical Microbiology, Landspitali University Hospital, Reykjavik, Iceland
7. National Reference Centre for Antimicrobial Resistance, Laboratory for Enterococci, University Hospital, Caen, France
8. REQUIMTE, Faculty of Pharmacy, University of Porto, Portugal
9. Faculty of Health Sciences, Fernando Pessoa University, Porto, Portugal
10. Swedish Institute for Infectious Disease Control, Stockholm, Sweden
11. Norwegian Surveillance System for Antimicrobial Resistance, University Hospital of North Norway, Tromsø, Norway
12. University Medical Centre Utrecht, Utrecht, the Netherlands
13. National Public Health Institute (KTL), Helsinki, Finland
Vancomycin-resistant enterococci (VRE) first appeared in the late 
1980s in a few European countries. Nowadays, six types of acquired 
vancomycin resistance in enterococci are known; however, only VanA 
and to a lesser extent VanB are widely prevalent. Various genes 
encode acquired vancomycin resistance and these are typically 
associated with mobile genetic elements which allow resistance 
to spread clonally and laterally. The major reservoir of acquired 
vancomycin resistance is Enterococcus faecium; vancomycin-
resistant Enterococcus faecalis are still rare. Population analysis 
of E. faecium has revealed a distinct subpopulation of hospital-
acquired strain types, which can be differentiated by molecular 
typing methods (MLVA, MLST) from human commensal and animal 
strains. Hospital-acquired E. faecium have additional genomic 
content (accessory genome) including several factors known or 
supposed to be virulence-associated. Acquired ampicillin resistance 
is a major phenotypic marker of hospital-acquired E. faecium in 
Europe and experience has shown that it often precedes increasing 
rates of VRE with a delay of several years. Several factors are known 
to promote VRE colonisation and transmission; however, despite 
having populations with similar predispositions and preconditions, 
rates of VRE vary all over Europe. 
Introduction
Enterococci are important hospital-acquired pathogens. Isolates 
of Enterococcus faecalis and Enterococcus faecium are the 
third- to fourth-most prevalent nosocomial pathogen worldwide. 
Acquired resistance, most prominently to penicilin/ampicillin, 
aminoglycosides (high-level resistance) and glycopeptides are 
reported in an increasing number of isolates and the therapeutic 
spectrum in these cases is limited. Therapeutic alternatives to 
treat infections with multi- and vancomycin-resistant enterococci 
(VRE) are restricted to antibiotics introduced recently into clinical 
practice such as quinupristin/dalfopristin, linezolid, tigecycline, 
daptomycin. However, these drugs are only approved for certain 
indications and resistance has already been reported [1-5]. 
Acquired resistance to glycopeptides is mediated by various 
mechanisms (types VanA/B/D/E/G/L; Table 1); the vanA and vanB 
resistance genotypes are by far the most prevalent in Europe. 
The reservoir for vanA- and vanB-type resistance in humans is 
E. faecium [6;7]. Consequently, increasing rates of VRE in 
several European countries are due to an increasing prevalence 
of vancomycin-resistant E. faecium (VREfm). Ampicillin- and/
or vancomycin-resistant E. faecalis (VREfs) are still rare [8]. 
Defined clonal groups of E. faecium show an enhanced capacity 
to disseminate in the nosocomial setting and are thus called 
epidemic or hospital-acquired [7]. These strains can be assigned to 
distinct clonal groups or complexes based on DNA sequence-based 
typing (multi-locus sequence typing - MLST) and phylogenetic 
analyses (eBURST) [6;7]. Hospital-acquired E. faecium are mostly 
ampicillin-resistant, partly high-level ciprofloxacin-resistant and 
possess additional genomic content, which includes putative 
virulence traits such as a gene for an enterococcal surface protein, 
esp, genes encoding different cell wall-anchored surface proteins, a 
putative hyaluronidase gene, hylEfm and a gene encoding a collagen-
binding protein, acm [6;7;9-12].
The current model predicts that spread of ampicillin-resistant, 
hospital-acquired E. faecium strains is a pre-requisite for successful 
establishment of VRE and further dissemination of vancomycin 
resistance among the hospital E. faecium population in general 
(see also following chapters). To a larger or lesser extent, non-
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microbiological factors such as antibiotic consumption (particular 
classes and in general); “colonisation pressure”, “understaffing”, 
compliance with hand hygiene and other infection control measures 
also influence this development [13-16]. Therefore, it might not 
come as a big surprise that despite having similar starting points 
and preconditions different countries experienced diverse trends in 
VRE prevalence. Already during the early and mid-1990s, epidemic 
clonal types of E. faecium were prevalent in hospitals in many 
countries, and this coincided in some European countries with 
a high prevalence of vancomycin resistance among E. faecium 
from animals and healthy volunteers linked to a widespread use of 
avoparcin as a growth promoter in commercial animal husbandry 
[14;17;18]. However, VRE rates in clinical isolates increased 
in many countries and peaked only almost ten years later when 
glycopeptide resistance had already declined in the non-hospital 
reservoir. Retrospective epidemiological analyses in hospitals 
experiencing larger VRE outbreaks revealed that changes in specific 
procedures such as antibiotic policy, staffing, infection prevention 
and control regimes were, in some instances, significantly 
associated with increasing VRE rates, whereas in other settings 
this could not be shown unambiguously. In addition, increased 
VRE prevalence is only partly associated with spread of single, 
distinct epidemic clones or types as known for pneumococci or 
methicillin-resistant Staphylococcus aureus (MRSA) [18-20]. VRE 
outbreaks in single centres tend to be polyclonal suggesting a 
highly diverse population of hospital-acquired E. faecium strains 
and a highly mobile resistance determinant capable of spreading 
widely among suitable recipient strains [21-23]. Many facets of 
VRE and vancomycin resistance epidemiology are currently not 
fully understood and the question why vancomycin resistance is 
still mainly limited to E. faecium remains unanswered.
 
Several national and European surveillance systems collect 
data on vancomycin resistance in enterococci. In some countries 
mandatory VRE surveillance is already established, in others coverage 
for the general population or selected settings is rather limited and 
the available data do not allow sound statistical analyses and in 
some countries data are completely lacking (see chapter 2). The 
most successful European antibiotic resistance surveillance scheme 
is the European Antimicrobial Resistance Surveillance System 
(EARSS) (http://www.rivm.nl/earss/) [8], which was established in 
1998 and is partly funded by the European Commission. EARSS 
collects data for selected antibiotic resistances in indicator bacteria 
exclusively from invasive (bloodstream) infections currently covering 
S. aureus, Escherichia coli, E. faecalis and E. faecium, Klebsiella 
pneumoniae and Pseudomonas aeruginosa. In 2006 over 800 
microbiological laboratories serving more than 1,300 hospitals 
from 31 countries provided susceptibility data from more than 
500,000 invasive isolates. Quality assessment is confirmed by 
annual external quality exercises. Despite the many advantages of 
an active European antimicrobial surveillance scheme, the huge 
amount of collected data cannot mask some of its drawbacks and 
limitations. Data collection and interpretation rely on different 
standards (Clinical and Laboratory Standards Institute - CLSI; 
European Committee on Antimicrobial Susceptibility Testing - 
EUCAST, British Society for Antimicrobial Chemotherapy - BSAC; 
etc.) and different methods (minimal inhibitory concentration - 
MIC determination; disk diffusion tests) used in the participating 
laboratories. What this means in practice has been documented 
by Leegaard et al. [24]. They tested a representative collection 
of strains and demonstrated, for instance, rates of MRSA among 
S. aureus isolates varying between 0 and 15 % depending on the 
standard applied. In an attempt to harmonise and standardise 
procedures for testing each bacterium/resistance combination, an 
EARSS manual was written in 2005; however, different methods 
and various standards are still being used which complicates 
the overall comparison of results. As the number of participating 
laboratories changes over time, distinct “resistance trends” may 
in some cases simply reflect organisational changes. Statistical 
coverage of the general population according to the number and 
country-wide distribution of contributing laboratories varies greatly 
between countries. Due to these limitations simple comparisons 
of surveillance data over time between countries or even within 
single countries should be done carefully (see also chapter 4 in 
T a b l e  1
Vancomycin resistance in enterococci. See cited reviews for details [96;97]
Acquired resistance Intrinsic resistance
phenotype VanA VanB VanD VanE VanG VanL VanC
ligase gene vanA vanB2 vanD2 vanE vanG2 vanL vanC
MIC vancomycin in mg/L 16 - 1000 4 - 32 (-1000) 64 - 128 8 - 32 16 8 2 - 32
MIC teicoplanin in mg/L (4-) 16 - 512 0,5 - 1 4 - 64 0,5 0,5 S 0,5 - 1
expression inducible inducible constitutive inducible inducible inducible constitutive/inducible
localisation plasmid/chromosome
plasmid/ 
chromosome chromosome chromosome chromosome chromosome? chromosome
























1 acquisition of vanA or vanB cluster in addition to vanC1 or vanC2/3 genes – rare event
2 subtypes exist (vanB1-3, vanD1-5, vanG1-2); S, susceptible to teicoplanin (no value given in the corresponding paper)
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the EARSS Annual Report 2006) [25]. A thorough study of the 
annual EARSS reports including all the available country-specific 
parameters provided in the annexes is essential for a critical 
and sound evaluation and interpretation of resistance data and 
trends. 
The following chapters give a detailed description of the current 
and past epidemiological VRE situation for different regions and 
countries in Europe. Several national experts were invited to 
describe local and regional differences and measures undertaken 
when facing first and limited VRE outbreaks or country-wide trends 
of VRE rates over the years.
Description of the epidemiological situation in Europe 
Northern Europe 
VRE surveillance in the Nordic countries, Norway, Denmark, 
Sweden, Finland and Iceland, is based on national public 
health programmes for containment of antimicrobial resistance, 
participation in EARSS and in some countries case notification from 
laboratories and clinicians. The Nordic countries have traditionally 
had a low prevalence of antimicrobial resistance, and this is also 
true for VRE. 
Since the mid 1990s, Norway, Denmark and Iceland have only 
registered sporadic cases and minor outbreaks of VRE infection 
or colonisation, often among patients transferred from hospitals 
in high-prevalence countries in Europe or the United States of 
America [26;27]. The annual number of cases has been 10–20 
in Denmark, 5–10 in Norway and single individual cases have 
been detected in Iceland. Hospital outbreaks of VREfm have in 
some cases been associated with concomitant dissemination 
of vancomycin-susceptible, ampicillin-resistant strains of the 
same clone [28-30]. As a consequence of previous exposure to 
the growth promotor avoparcin in animal husbandry, significant 
animal reservoirs of VREfm have been reported from both Denmark 
and Norway. Individual examples of a possible clonal relationship 
between human clinical strains and isolates of animal origin have 
been detected [31], but the clinical impact in terms of human 
VRE infections has been limited. The VRE reservoirs in animal 
husbandry have been substantially reduced since avoparcin was 
banned in 1996.
The epidemiology of VRE colonisation and infections is somewhat 
different in Sweden and Finland. The Helsinki area experienced 
an epidemic of VRE affecting patients in haematological and 
other internal medicine wards in several hospitals in 1996-1997 
[32;33]. The outbreak involved two different E. faecium clones 
which harboured either vanA, vanB or both determinants. A number 
of vancomycin-susceptible E. faecium (VSEfm) isolates shared the 
same macrorestriction pattern in pulsed-field gel electrophoresis 
(PFGE) as the outbreak strains. Investigation of the outbreak 
suggested that vanA and vanB clusters were incorporated into an 
endemic ampicillin-resistant VSEfm strain. Over the last ten years, 
the situation in Finland has been stable with 30–60 cases of VRE 
infection or colonisation each year being reported from different 
counties. 
In Sweden, the situation has been stable with 18–53 cases of 
VRE infections and colonisations being reported annually between 
2000 and 2007, and with a prevalence of VRE among Swedish 
enterococcal bloodstream isolates below 0.5% until 2006 [34;35]. 
However, the situation is rapidly changing with the predominant 
spread of a vanB E. faecium clone, but also of other strains, among 
more than 200 patients in Stockholm and several other counties 
since autumn 2007 (http://www.smittskyddsinstitutet.se/in-english/
statistics/vancomycin-resistant-enterococc-infection-vre/). Given 
this situation one may fear that VRE will become established as 
an endemic hospital pathogen in parts of Sweden. 
The Nordic countries have been relatively successful in containing 
MRSA. This has been achieved through strict enforcement of 
infection control measures such as contact isolation of known cases, 
screening for MRSA among patients and healthcare workers exposed 
to MRSA or arriving from high-prevalence areas, and eradication 
of MRSA colonisation. These strategies have been written into 
local guidelines and national regulations. Finland issued specific 
national guidelines for VRE in conjunction with the outbreak in 
1996-1997, and patients in Sweden are presently screened for VRE 
applying the MRSA guidelines. In Denmark, Norway and Iceland 
VRE is not subject to the same level of regulation as MRSA. Many 
institutions will screen patients who may have been exposed to 
VRE, but the extent of screening as well as the isolation regimen 
used is based on local assessment. One can expect more explicit 
national guidelines in these countries if the prevalence of hospital 
VRE increases further.
United Kingdom and Ireland
There is no single comprehensive surveillance scheme for 
monitoring VRE infections in the United Kingdom (UK). However, 
bacteraemia caused by VRE is monitored by four complementary 
surveillance programmes, with varying degrees of coverage and 
participation: 
• Department of Health mandatory glycopeptide-resistant 
enterococcal bacteraemia reporting scheme [36;37], collecting 
the total number of VRE bacteraemias in England each year;
• Health Protection Agency (HPA) LabBase2 reporting, voluntary 
surveillance scheme, collecting VRE data from England, Wales 
and Northern Ireland [38];  ascertainment of cases not as 
complete as in mandatory reporting; 
• British Society for Antimicrobial Chemotherapy (BSAC) 
Bacteraemia Surveillance Programme [39], sentinel surveillance 
programme, collecting isolates from 25 centres in the UK 
and Ireland each year, providing high-quality centralised 
investigation of the isolates; and 
• EARSS [8], collecting VRE data from England and Wales. 
Based on data from all four surveillance programmes estimates 
for the proportion of enterococcal bacteraemia attributable to VRE 
for the UK as a whole in 2007 are 8.5-12.5% for all enterococci, 
20 - 25% for E. faecium and 1.6-2.5% for E. faecalis [8;37;39]. 
There are other surveillance programmes monitoring VRE prevalence 
in Wales and Scotland but, although some recent data from these 
are available, more data are required to assess trends over time. 
However, the VRE rate reported for Wales in 2006 was similar to 
that determined in the BSAC surveillance for Wales, 15.5% versus 
11.9% respectively [40]. The HPA’s Laboratory of Healthcare-
Associated Infections offers to ‘type’ VRE to assist local outbreak 
investigations, but currently there is no initiative to undertake 
detailed molecular epidemiological investigations of VRE on a 
national level in the UK.
Between October 2006 and September 2007, 910 VRE 
bacteraemia cases were reported by English hospitals via the 
mandatory VRE surveillance [36]. Among the acute National Health 
Service (NHS) Trusts that reported data, 24 (14%) reported >10 
cases, 94 (55%) reported 1-10 cases, and 53 (31%) had no cases. 
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The majority of Trusts reporting >10 cases were acute teaching 
Trusts. VRE is not a high profile cause of invasive infection in the 
UK; VRE is eclipsed by more profuse pathogens with, for example, 
4,438 MRSA bacteraemias [41] and 50,392 Clostridium difficile 
cases reported by the Department of Health’s mandatory reporting 
schemes over the same time period [42]. In consequence, VRE 
does not “enjoy” the same degree of political and press attention 
as MRSA and C. difficile. 
Table 2 shows the prevalence of VRE found by three of the 
surveillance programmes operating in the UK, which provide 
sufficient data to show trends over time and the proportion of 
overall enterococcal bacteraemias they comprise. As the data in 
Table 2 is derived from surveillance programmes with differing 
coverage of UK regions and levels of participation, it is not possible 
to compare the figures directly. However, the data allow VRE trends 
to be approximated and similar trends present in various datasets 
add to its validity. The LabBase and BSAC surveillance data show 
that the prevalence of VRE among enterococcal bacteraemias has 
increased from 2001–2006. EARSS only started to determine 
VRE prevalence from 2005 and VRE numbers from this survey 
appear to have dropped by approximately 50% from 2005 to 
2007. However, it is too early to conclude whether this represents 
a reliable downward trend since, unlike the mandatory and LabBase 
programmes, EARSS collects data from a relatively small number 
(n= 23) of  study centres, and is therefore more susceptible to 
year-to-year variation within a single centre. The same applies for 
the BSAC study. Moreover, mandatory data show that the numbers 
of cases vary between hospitals from 0 to >10. Variation between 
the surveillance schemes might thus reflect regional variation and 
the types of hospitals participating in the different schemes. As 
the mandatory reporting scheme does not collect total numbers 
of enterococcal bacteraemias, it is not possible to determine VRE 
prevalence from this dataset. However, mandatory reporting has 
shown an increase in the number of VRE bacteraemias since the 
inception of the scheme in 2004 [36].
Unlike the mandatory reporting scheme, the LabBase, BSAC and 
EARSS surveillance programmes record the identification of VRE to 
species level and collect susceptibility data on antibacterial agents 
in addition to vancomycin. Figure 1 compares the resistance to 
vancomycin in E. faecium and E. faecalis as seen in the LabBase 
surveillance 1994-2007. As with the LabBAse data the other 
surveillance programmes show that the majority of VRE in the UK are 
E. faecium, and that the bulk of VRE have the VanA phenotype, with 
non-susceptibility to both vancomycin and teicoplanin [37;38]. A 
recent review of data from 2001-2006 from the BSAC bacteraemia 
survey [37;39] showed that VRE bacteraemia isolates were most 
likely to be from patients who had been in hospital for more than 
48h, and were associated with haematology/oncology patients. 
Inter-centre variation of VRE prevalence was also highlighted, with 
54.1% of vancomycin non-susceptible isolates coming from just 
six out of all 29 centres participating in the study [37]. None of 
the current VRE surveillance programmes collect data on antibiotic 
prescribing so it is not possible to tell whether high rates of VRE 
are related to prescribing policy at these centres. 
Ireland has been contributing resistance data for enterococci 
to EARSS since 2002 with an excellent coverage of almost 100% 
in the last years. Rates of VREfm increased the first years of 
reporting from 2002–2005 due to new laboratories joining and 
lower coverage and levelled off at 30 – 35% from 2005 on. Rates 
of VREfs increased slightly but remained below 5%.
France
Before 2005, only sporadic cases or outbreaks with a limited 
number of cases due to VRE were reported in France. The incidence 
of glycopeptide resistance in E. faecium from bacteraemia 
remained below 5% [8]. Despite this reassuring picture, large 
outbreaks affecting several hundreds of patients occurred in 2005 
in a few hospitals and these prompted the French authorities to 
recommend in 2005 and 2006 notification of all cases of infections/
colonisations due to VRE. Furthermore the implementation of strict 
infection control measures was also recommended (http://cclin-
sudest.chu-lyon.fr/Alertes/ficheERV_CAT_112006.pdf) [43]. In 
addition, isolates should be sent for analysis to the Laboratory 
for Enterococci, which is part of the French Reference Centre for 
Antimicrobial Resistance. In 2006, 93% (26/28) of hospitals that 
notified VRE cases also sent the isolates to the Reference Centre; 
this percentage decreased to 50% in 2007 but reached 100% in the 
T a b l e  2
Prevalence levels of vancomycin-resistant entrococci (VRE) among 
enterococcal bacteraemia cases as reported by three different 
surveillance programmes with varying amounts of region coverage 
and participation, United Kingdom, 2001-2007
Year LabBasea BSACb EARSSc
2001 9.1% 8.1% N/A
2002 9.1% 8.5% N/A
2003 9.3% 10.2% N/A
2004 10% 11% N/A
2005 10.7% 16% 14.9%
2006 11.5% 12.6% 6.9%
2007 12.2% Data not yet available 8.5%
a LabBase data obtained from English, Welsh and Northern Irish (from 2002) 
hospitals
b British Society for Antimicrobial Chemotherapy (BSAC) sentinel surveillance 
covering the United Kingdom and Ireland
c European Antimicrobial Resistance Surveillance System (EARSS) sentinel 
surveillance covering England and Wales
N/A, data not provided
F i g u r e  1
Resistance to vancomycin in Enterococcus faecium and E. faecalis 
from bacteraemia, England, Wales and Northern Ireland, 1994-2007 
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first six months of 2008. Overall, it is assumed that the Reference 
Centre has analysed isolates from the major outbreaks occurring 
in France since 2005. Among 507 isolates analysed, 27 were 
obtained from blood cultures, 30 from various suppurations (mostly 
intra-abdominal), 10 from intravenous catheters, 68 from urine and 
372 from rectal swabs. The latter isolates were obtained during 
faecal screening, which is part of infection control measures. This 
distribution confirms the low ratio of infection versus colonisation 
for VRE. The vast majority of isolates were E. faecium and E. 
faecalis and contained the vanA or vanB genes; vanA E. faecium, 
vanB E. faecium, vanA E. faecalis and vanB E. faecalis represented 
78.2%, 18%, 3% and 0.8% of isolates, respectively.
Variation in the number of isolates received by the Reference 
Centre in different years corresponds to changes in the type and 
numbers of hospitals affected by outbreaks. In 2005–2006, most 
isolates were from large outbreaks of vanA E. faecium occurring 
in hospitals in Paris and central France (Clermont-Ferrand) and 
smaller outbreaks in other hospitals. In 2007, the number of 
isolates sent by these hospitals markedly decreased suggesting 
that these outbreaks were controlled. However, other hospitals, in 
the east of France in 2007, and then in the north and east of France 
in 2008, faced vanA E. faecium outbreaks. In the beginning of 
2008, spread of vanB E. faecium isolates was observed in several 
hospitals from the north of France. 
PFGE analysis revealed clonal diversity among VRE. Generally, a 
few (one to four) predominant clones and several other clones (up 
to twelve) spread in an affected hospital. In general, each hospital 
has specific clones, distinct from those of other hospitals. However, 
as expected, we observed that, in several cases, strains can spread 
between neighbouring hospitals that frequently exchange patients. 
Typing by MLST and subsequent eBURST analysis showed that 
all typed isolates from the predominant clones in France of the 
French major clones belonged to hospital-acquired clonal types 
(clonal complex CC17). Sequence types ST78 and ST18 are the 
most frequently isolated. The presence of the esp and hylEfm genes 
is variable.
As already reported for these hospital-acquired E. faecium 
strains, the studied E. faecium isolates were highly resistant to 
ampicillin and fluoroquinolones, no matter whether they contained 
the vanA or the vanB gene. Vancomycin resistance was usually 
expressed at high levels for isolates containing the vanA gene. 
However, a particular clone isolated in Paris had a heterogeneous 
and low-level expression of vancomycin resistance [44]. High-level 
resistance to gentamicin was expressed by 59.6% of the tested 
strains and was associated with specific clones. All isolates were 
susceptible to linezolid, tigecycline and daptomycin.
In conclusion, vanA-carrying E. faecium are highly predominant 
in France although outbreaks due to vanB E. faecium recently 
emerged. Isolates share the characteristics of representatives of the 
clonal complex of hospital-acquired types (CC17) but sometimes 
lack the esp and hylEfm genes.
Central Europe
Austria has reported resistance data for enterococci to EARSS 
since 2001. Austrian EARSS data are also included with a more 
detailed description in the National Antibiotic Resistance and 
Consumption Report AURES (http://www.ages.at/uploads/media/
AURES_2004_04.pdf; accessed 20 October 2008). The number 
of laboratories participating in EARSS increased annually. In 2006 
a total of 33 laboratories participated, serving a balanced mixture 
of hospitals of primary, secondary and tertiary care and provide 
a high coverage of the total population (87%; [25]). Resistance 
to vancomycin is rare; rates of VREfs or VREfm were ≤1% from 
2003-2006 with a slight increase for VREfm in 2007 (1.9%). 
VREfm rates of 4% in 2001 and 5% in 2002 may be related to and 
thus biased by the low number of participating laboratories in the 
beginning. There is one report of an outbreak caused by a single 
VRE clone in a large teaching hospital attributed to inadequate 
infection control measures [45]. The increasing rate of ampicillin-
resistant E. faecium, from 67% in 2001 to 89% in 2006, suggests 
a wide dissemination of hospital-acquired clonal types similar to 
many other European countries. AURES also reports resistance 
in indicator bacteria showing that the reservoir of vancomycin 
resistance among colonising  E. faecalis and E. faecium in animal 
husbandry (poultry, pigs and cows) is low (<1%). 
EARSS data from Germany are based on a varying number of 
participating laboratories since 1999 and are associated mainly 
with tertiary care hospitals. The number of participants dropped 
after 2004 to 15 reporting laboratories in 2006. This corresponds 
to a catchment population of only 2%. Hence it is questionable 
how representative those figures are on a national scale and it 
is important to compare them with data from other surveillance 
schemes. German EARSS data state an increase in VREfm from 1% 
in 2001 via 11% in 2004 to 8 % in 2006 rising again to 15% in 
2007. It can be expected that rates vary due to annual differences 
in the number and composition of participating laboratories and 
do not reflect true epidemiological trends. The percentage of 
ampicillin-resistant E. faecium (AREfm); however, constantly 
increased to reach a level of >90% after 2004 suggesting wide 
distribution of hospital-acquired E. faecium strains. The prevalence 
of VREfs remains at <1%.
There are several German resistance surveillance systems 
reporting vancomycin resistance rates and resistance development 
in enterococci supporting or adding to the results of EARSS. The 
longest established surveillance project is that founded by the 
Paul Ehrlich Society for Chemotherapy Task Force Susceptibility 
Testing and Resistance (http://www.p-e-g.org/ag_resistenz/main.
htm; accessed 20.10.2008). Around 30 laboratories in Germany, 
Austria (n= 3) and Switzerland (n= 3) participate. Every three years 
consecutive isolates exclusively from infections (no repeat isolates) 
are collected for several weeks and antimicrobial resistance is 
determined using standardised broth microdilution methods. 
Results for enterococci have been reported since 1990 (for E. 
faecium since 1995). The two main findings showing that rates 
of VREfs are still below 1% and rates for VREfm increased during 
the last three studies from 2.7% in 2001 to 13.5% in 2004 and 
11.2% in 2007 confirm results of other surveillance schemes 
(http://www.p-e-g.org/ag_resistenz/main.htm).
Founded in 1999 the German Network for Antimicrobial 
Resistance Surveillance (GENARS; http://www.genars.de/index.
htm) collected data on clinical and surveillance isolates from five 
to seven major German tertiary care hospitals. All participants 
use the same methodology (MIC testing by broth microdilution), 
data/isolates are collected permanently and evaluated biannually. 
Results for 2002 to 2006 show an increase in the rates of VREfm 
from 0.9% in the first half of 2002 to 15.3% in the second half of 
2006. Vancomycin resistance is rare in E. faecalis from GENARS 
hospitals (<1%). 
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Increased VREfm prevalence in Germany was first noted in 
south-western German hospitals in 2003 and marked by several 
outbreaks in hospitals in Baden-Württemberg. In this context, data 
from a major laboratory service provider (laboratory Dr. Limbach 
and colleagues, Heidelberg, Germany) supporting a large number 
of hospitals in different neighbouring federal states in this area are 
of special interest. They showed increasing VREfm rates several 
months before this manifested as a national trend (compared to 
GENARS and EARSS data). Between the first and second half of 
2003 VREfm rates increased threefold (4% versus 13%) whereas 
the number of sampled E. faecium isolates remained constant. 
About 10% of all sampled enterococci were E. faecium (1998: 
2.6%; 2002: 3.5%) and VREfm rates vary between 18% and 
28% indicating still the highest VRE prevalence in this part of 
Germany. 
In February 2000 an interdisciplinary project called Surveillance 
of Antibiotic Use and Resistance in Intensive Care Units (SARI) was 
initiated (www.antibiotika-sari.de). SARI collects data on antibiotic 
resistance in nosocomial pathogens exclusively from intensive care 
units (ICU) (n= 47 ICUs from 25 hospitals in 2006) and links them 
with numbers for antibiotic consumption. Rates for VREfm vary 
between 0.6% in 2002 and 5.6% in 2005, with a rate of 2.6% 
in 2007. So far, a definite trend could not be demonstrated in the 
data and the peak in 2004-2005 was due to VREfm outbreaks 
in single, participating ICUs in south-west German hospitals. 
Intriguingly, VRE outbreaks could not be linked statistically to 
changing antibiotic policies, increasing antibiotic consumption in 
general or for special substances, change in staffing, changes in 
infection control measures, etc. Interestingly, the VRE trend did 
also not follow the MRSA trend in the corresponding SARI ICUs. 
Molecular epidemiological investigations of several outbreaks 
and clusters of infections in German hospitals indicated that 
clonal spread of different epidemic VREfm strains and lateral gene 
(plasmid) transfer between unrelated enterococcal recipient strains 
contributed to increasing VREfm rates (not described in details) 
[20;46].
Initiatives are currently underway to consolidate the different 
national surveillance schemes under a single coordinating centre - 
the Robert Koch Institute- and with funding by the Federal Ministry 
of Health, Germany. The eventual goal is to combine all efforts into 
a single national surveillance scheme for antimicrobial resistance 
and consumption providing up-to-date, reliable and comparable 
data with high coverage. 
For Belgium, 24 laboratories submitted data for enterococci 
to EARSS. Belgium has had high MRSA rates in recent years and 
several national initiatives and campaigns have been started to 
target this problem. According to EARSS data, rates of VREfm 
increased sharply from 2004 to 2005 from 0 to 14% but decreased 
again to <1% in 2007. Fluctuations may be related to the varying 
number of participating laboratories and a few outbreaks during 
the study period in single institutions [22] that biased the strain 
collection. The disproportionate numbers for MRSA and VRE rates 
indicate that high MRSA prevalence over a longer time does not 
necessarily lead to increasing VRE rates.
Switzerland, not being a member of the European Union (EU), 
established its own resistance surveillance project called SEARCH 
(Surveillance of Antibiotic Resistance in Switzerland; http://www.
search.ifik.unibe.ch/de/index.shtml). This project was established 
as part of the National Research Programme NRP49 “Antibiotic 
Resistance”. Corresponding resistance data from 2007 onwards will 
be integrated into the EARSS platform. SEARCH will be extended 
later on to data on antibiotic consumption. In general, antibiotic 
resistance is low in Switzerland. Results for 2007 show 1.5% and 
1.1% vancomycin resistance among E. faecium and E. faecalis, 
respectively. About 80% of all E. faecium isolates are ampicillin-
resistant showing wide distribution of hospital-acquired clonal types 
for Switzerland. 
Southern Europe
The highest rates of VRE associated with nosocomial infections 
in Europe were reported in some countries of southern Europe with 
levels up to 45% detected in recent years in Greece and Portugal 
[8]. As observed in other geographical regions, vanA E. faecium 
isolates were mainly responsible for the high rates of infections 
caused by VRE in Greece, Portugal and Italy [8;47-50].
The System for the Surveillance of Antimicrobial Resistance in 
Greece has provided VRE data to EARSS through the participation 
of an increasing number of hospital laboratories (n=12 in 2000, 
n=39 in 2004), mostly associated with hospitals providing 
secondary care and now covering around 75% of the population 
[8]. VREfm rates significantly increased from <1% in 2000 to 42% 
in 2006, with a slight decrease registered in 2007 (37%). As in 
other European countries, lower glycopeptide resistance rates for 
E. faecalis (<10 %) have been maintained in most years [8]. The 
few available studies concerning molecular characterisation of 
Greek VRE described a polyclonal multidrug-resistant E. faecium 
population with hospital-acquired, epidemic strains [47;49]. There 
is one report of an outbreak caused by a single VREfs clone in a 
large hospital attributed to inadequate infection control measures 
[51].
The first large VRE surveillance study in Portugal which included 
data from ten participating hospitals was performed in 1994 and 
revealed rates of 1% of VREfs and 9% of VREfm among isolates 
causing urinary tract and invasive infections [52]. A remarkable 
increase in VREfm was documented in subsequent years with rates 
rising from 20% in 1996 (for the same 10 hospitals screened in 
1994) to 47% in 2003 [8;53]. Decreasing VREfm rates reported 
by EARSS in 2007 (29%) may indicate the implementation of 
successful infection control measures. In Portugal, antibiotic 
resistance data have been collected by an increasing number of 
EARSS-participating laboratories: 12 in 2001, 20 in 2006, mostly 
from tertiary care hospitals providing nowadays a coverage of almost 
90% of the total population. Although polyclonality was frequently 
observed among VREfm, intra- and interhospital dissemination 
of persisting E. faecium and E. faecalis clones and specific vanA 
transposon (Tn1546) types seemed to have contributed to the rapid 
and extensive spread of VRE in Portuguese hospitals [48;54;55]. A 
high proportion of VREfm isolates was also resistant to ampicillin 
(70 - 74% between 1994 and 2006) [8;52], which together with 
MLST data suggests wide dissemination of epidemic clones among 
Portuguese hospitals [48;56; unpublished results]. 
In Italy, a large multicenter study carried out between 1993 
and 1995 reported 9% of E. faecium isolates were resistant to 
vancomycin [57]. Since 2001, the Italian Antibiotico-resistenza-
Istituto Superiore di Sanitá has provided VRE data to EARSS 
through laboratories of secondary care hospitals (35 participating 
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laboratories in 2006 and 49 in 2002), which currently cover around 
10% of the population. VREfm rates increased from 15% in 2001 
to 24% in 2003, but decreased to 11% in 2007. The frequency 
of VREfs has increased but has remained below 5% during the 
entire period (from <1% in 2002 to 4% in 2006) [8]. The first 
clonal outbreak caused by VRE in Italy was reported in an ICU 
in 1996 and since then clonal outbreaks have been reported in 
different hospitals [50;58;59]. Nationwide spread of an E. faecium 
vanA strain causing infections in different cities from 2001 to 
2003 was also described [50]. Most VREfm strains associated with 
human infections which were characterised since 1993 have been 
multidrug-resistant and have clustered with hospital-acquired clonal 
types [19;50;60]. Horizontal transfer of Tn1546 also seemed to 
contribute to the recent spread of VRE in Italy [61]. 
EARSS data from Spain have been available since 2001 and are 
provided by a constant number of approximately 35 laboratories of 
secondary care hospitals [8]. Rates of VRE in Spain remain among 
the lowest in EU Member States: <1% of VREfs and 1-3% of VREfm 
between 2001 and 2003. However, self-limited hospital clonal 
outbreaks caused by vanA E. faecalis have been reported between 
1994 and 2006 [62;63]. VanB E. faecium clonal outbreaks were 
initially described in 2001 but remained rare until recently. The 
description of two large clonal outbreaks caused by vanB E. faecium 
in different cities in the north-west area in 2004 and 2006 and 
the recent interhospital dissemination of a particular clone deserve 
attention [64-67]. Representative isolates of most of these outbreak 
strains belong to E. faecium and E. faecalis epidemic clonal types 
(VREfm: CC17 and VREfc: CC2/CC9) [68]. 
Despite the very low prevalence of VREfm in Spain, a dramatic 
increase in E. faecium resistant to high levels of ampicillin has 
been detected, rising from 49% in 2001 to 73% in 2006 [8]. 
These epidemic AREfm strains might facilitate a future increase 
in VREfm in this country [65;66;69].  
Eastern and south-eastern Europe
The first reports of VRE in Poland date back to the second half 
of the 1990s when the first vancomycin- and teicoplanin-resistant 
(VanA phenotype) isolates of E. faecium were obtained from 
three patients in the adult haematology ward of Gdansk Medical 
University in late 1996/early 1997 [70]. All these isolates showed 
the presence of the vanA gene, but were genetically unrelated 
in PFGE analysis. A subsequent study in the same ward showed 
that vanA-positive E. faecium accounted for almost 50% of this 
species (49 VREfm from 29 patients) [71]. The 1997–1999 VRE 
outbreaks in the adult and paediatric haematological wards of 
the Gdansk Medical University showed the involvement of two 
distinct polymorphs of the vanA gene cluster and two types of 
Tn1546-like transposons [72]. These determinants were most 
probably introduced into the hospital independently, resulting 
in a complex epidemiological situation involving both horizontal 
gene transfer among unrelated strains of E. faecium and a single 
isolate of E. faecalis, as well as the clonal spread of VRE in the 
two wards. The first vanB E. faecium, harbouring the vanB2 gene 
variant, was found in a patient undergoing prolonged vancomycin 
therapy in an ICU ward of one of Warsaw’s hospitals in 1999 
[73]. The introduction of appropriate infection control procedures 
prevented the further spread of VRE within the hospital. During the 
period of 1999–2000, an outbreak of vanB enterococci occurred 
independently in another Warsaw hospital which specialised in 
haematological disorders [74]. PFGE and MLST analyses of VREfm 
and VSEfm recovered concomitantly in the same hospital suggested 
that the resistance determinant was introduced into a locally 
persisting strain (unpublished results). Similar to other countries, 
most of the recorded VRE outbreaks in Poland were caused by E. 
faecium and E. faecalis. In contrast, an unusual mixed outbreak of 
E. faecium and E. raffinosus, both of which carried the vanA gene 
occurred in 2005 in the haematology, nephrology and surgery wards 
in Krakow [23]. Despite these sporadic outbreaks and documented 
local VRE prevalence, EARSS data for Poland do not suggest a 
general VRE problem in the country. However, data have to be used 
with caution since coverage and the number of investigated isolates 
per year is low, especially those for E. faecium [8]. 
In the Czech Republic, systematic screening for VRE in patients 
hospitalised at the Department of Haemato-Oncology, Olomunc 
University Hospital (Moravia region), started in 1997 [75], and the 
first isolates of VRE were identified the same year [76]. Between 
1998 and 2002, VRE remained at the level of 4.9 to 6.8% of all 
enterococcal isolates in the hospital. E. faecium of the vanA-type 
were most frequent, almost 80% of all VRE, followed by vanB E. 
faecalis. PFGE and vanA cluster analyses showed presence of three 
major clonal groups of E. faecium, of which one predominated in 
1998-1999 and another in 2001-2002. Tn1546 transposon typing 
confirmed the role of horizontal spread of resistance determinants 
among these strains and suggested several independent acquisitions 
of different Tn1546 variants [76;77]. Locally and country-wide 
VRE rates increased in subsequent years [8]. VRE screening in 
samples from the general population and from poultry revealed 
prevalence outside the nosocomial setting, but there was no 
molecular evidence to support a recent exchange of strains or their 
resistance determinants between the animal or human commensal 
and the nosocomial setting [77-79]. 
Reliable data for VRE prevalence in Slovakia are missing [8]. 
Enterococci from slaughtered animals (poultry, swine, cattle) in 
Hungary from 2001-2004 showed a decreasing VRE prevalence 
after the discontinuation of avoparcin use since 1998 [80;81]. 
According to published reports and EARSS data VRE are rarely 
encountered among Hungarian hospital patients [8;82]. The limited 
data available to estimate VRE rates for the Baltic countries (Latvia, 
Lithuania, Estonia) suggest absence of any VRE cases or outbreaks 
[8]. Reports about VRE cases or outbreaks in hospitals in south-east 
European EU countries such as Romania and Bulgaria are lacking, 
data from EARSS show no VRE cases, but data are only provided by 
a few laboratories with low overall coverage of the population [8]. 
EARSS data for Slovenia appear comprehensive and demonstrate 
the country’s first VRE cases in 2006.
The Netherlands – an example of a low prevalence country
In the Netherlands, antibiotic resistance data from different 
bacterial species, including VRE, isolated from various clinical 
specimens like blood and urine are collected in the Electronic 
Laboratory Surveillance Program - ISIS. Furthermore, an increasing 
number of laboratories participated in EARSS, rising from eight 
in 2001 to 23 in 2006, with an estimated coverage of 69% of 
the Dutch population [8;25]. Despite a few major outbreaks in 
several hospitals in 2000 [26,83,84], the prevalence of VRE 
among bloodstream isolates has been consistently low (<1%) over 
the years, which is probably due to prudent use of antibiotics 
and a “search and destroy” policy in Dutch hospitals for both 
VRE and MRSA [25]. Although VRE prevalence rates are low, data 
from a recent nationwide study revealed a significant increase in 
invasive AREfm in the Netherlands [85]. Average annual numbers 
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of ampicillin-resistant enterococci from normally sterile body sites 
per hospital increased from 5 (standard deviation - SD 1) in 1994 
to 25 (SD 21) in 2005. The increase was most pronounced in 
university hospitals (from 5 SD 1 in 1994 to 47 SD 17 in 2005) 
(Figure 2). Furthermore, among all enterococcal bacteremias, 
the proportion of AREfm increased from 4% in 1994 to 20% 
in 2005. A previous study from the University Medical Center 
Utrecht (UMCU) revealed that although the overall number of 
patients with invasive enterococcal infections decreased between 
1994 and 2005, the proportion of invasive AREfm increased from 
2% in 1994 to 32% in 2005, which suggests replacement of E. 
faecalis by AREfm. In the same study, monthly point-prevalence 
studies performed to determine the intestinal AREfm reservoir on 
seven hospital wards revealed carriage rates ranging from 0% in 
dermatology to 35% in haematology and geriatric wards. In another 
three-month study performed in the UMCU, ARE acquisition and 
environmental contamination rates were determined on two wards, 
haematology and a mixed gastroenterology/nephrology ward, where 
AREfm are endemic. This study revealed high levels of AREfm 
acquisition (15-39%) and environmental contamination (22%) in 
combination with selective antibiotic pressure [86]. In addition, 
a relatively high number of patients were already colonised with 
AREfm upon hospital admission, which was most probably due to 
frequent readmission [86]. Genotyping of the AREfm isolates from 
the different studies revealed that four genetically related AREfm 
types emerged nationwide, and that these were distinct from E. 
faecium belonging to the indigenous commensal flora [85;86]. 
The emergence of hospital-acquired AREfm will impact on the 
treatment of enterococcal infections. The preferred antibiotic for 
invasive enterococcal infections, ampicillin, must be replaced by 
more expensive and toxic antibiotics like vancomycin, linezolid or 
daptomycin.
The Dutch Working party “Infection Prevention” has developed 
guidelines with measures to prevent transmission of highly resistant 
microorganisms (HRMO), including E. faecium (http://www.wip.nl/). 
In these guidelines E. faecium is considered an HRMO when the 
strain is resistant to both ampicillin and vancomycin and isolation 
of patients is indicated only in those cases. Ampicillin-susceptible 
VREfm isolates are considered animal derived. Isolation of patients 
with these strains is not indicated, because these strains do not 
spread in hospitals and ampicillin can still be used as the first 
choice drug to treat these strains.
Concluding remarks
Different types of gene clusters encoding vancomycin and partly 
teicoplanin resistance have been identified in enterococci; the 
vanA and to a lesser extent the vanB types are widely prevalent 
in Europe and worldwide. Both determinants are part of larger 
mobile genetic structures and thus are transferable via clonal 
dissemination and lateral gene transfer. On very few occasions, 
the vanA gene cluster has spread to S. aureus constituting the 
first seven cases of vancomycin-resistant S. aureus (VRSA); these 
cases emerged independently in northern America [87;88]. 
Acquired vancomycin resistance appears to be a serious and 
growing therapeutic challenge among enterococci all over Europe 
(Figure 3). Some EU countries have experienced an increasing 
VRE trend over time (e.g., Ireland, Germany, Greece). In other 
F i g u r e  2
Average number of invasive ampicillin-resistant enterococci 
per hospital in university and non-university hospitals*, the 
Netherlands, 1994-2005
Note: Error bars denote standard deviations. 

































































F i g u r e  3
Prevalence of vancomycin resistance among clinical Enterococcus 







The estimated rates were mainly based on results of EARSS reporting 
resistance in invasive (bloodstream) isolates. For single countries also data 
from other surveillance schemes have been considered and an estimated 
average prevalence rate is presented. Countries with prevalence data are 
coloured in light blue, countries with no reliable data are shown in white. 
See Figure legend code I to VI for vancomycin resistance rates among 
E. faecium. The authors would like to advise using the presented data in 
this figure cautiously and recommend not to overestimate results for single 
European countries (see also critical comments stated in the EARSS annual 
reports (25)).
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countries VRE prevalence is still low (e.g., in Nordic countries, the 
Netherlands). A few EU Member States showed decreasing VRE 
rates (e.g., Austria, Portugal, Italy); however, the reasons for this 
trend remain unclear since it could not be linked unambiguously to 
definite measures like stricter antibiotic usage patterns, application 
of alternative antibiotic policies, an activated surveillance or an 
improved infection control and prevention scheme including hand 
disinfection. Nevertheless, individual countries’ experiences with 
VRE outbreaks and enhanced understanding of the risk factors 
associated with VRE acquisition, lead to a wider acceptance of 
active control and prevention strategies such as VRE screening for 
“at risk” patients [22;89]. Improvements in VRE diagnostics by 
extended automated systems, new manual approaches like new 
agar screening plates supplemented with chromogenic substrates 
and more reliable screening tests (for instance via real-time PCR) 
improve the early detection of VRE carriers and cases and thus 
enable rapid measures to reduce the risk of transmission within the 
clinical setting [90;91]. The wide distribution of (still) vancomycin-
susceptible, but ampicillin-resistant hospital-acquired clonal types 
of E. faecium among hospitals European-wide is worrisome, since 
vanA/B determinants predominantly spread among E. faecium and 
experience from the US and other countries with high VRE rates show 
that increasing VRE rates follow several years after (vancomycin-
susceptible) hospital-acquired E. faecium clonal types become 
established in the clinical environment [7;92]. Early recognition of 
epidemic E. faecium strains is critical but standardised methods 
for rapid diagnostics are missing. Acquired ampicillin and high-
level ciprofloxacin resistance appear as good phenotypic markers 
of hospital-acquired E. faecium strains [7;10;92;93]. However, 
molecular markers such as the esp gene or the purK1 allele (used 
as part of the MLST scheme) are not ubiquitous traits of hospital-
acquired E. faecium strains and failure to detect them does not 
reliably indicate a strain with limited spreading or pathogenic 
potential [12;20;60;94]. There is an urgent need for a reliable 
and rapid molecular test to differentiate commensal from hospital-
acquired strains; results from comparative genomic hybridisations 
and genome sequencing projects may come up with some promising 
candidate determinants [9;95].  
The situation regarding VRE in Europe is diverse with prevalences 
ranging from <1 to >40% and many aspects of VRE acquisition 
and spread are still unknown. On one side we find increasing 
numbers of epidemic strains and mobile resistance determinants 
and on the other side a hospital environment with a permanently 
growing patient population “at risk” for acquiring multi-resistant 
pathogens. Increasing numbers of such multi-resistant pathogens 
call for prescription of increasingly more and modern antibiotics 
leading to a “vicious cycle” of growing resistance development. 
Countries, regions and hospitals with low VRE prevalence are 
advised implement a strict “search and destroy”-like policy 
– experience gained from MRSA and other hospital-acquired 
pathogens has taught us that multi-resistant pathogens can only 
be partly controlled once established in the nosocomial setting. 
While great efforts can be rewarded by decreases in prevalence of 
resistance, it is probably unlikely ever to return to 0%.
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